Artificial intelligence-empowered 4D bioprinting for craniomaxillofacial
The International Society for Stem Cell Research brought scientists, doctors, and innovators together in Kyoto for a fully booked meeting celebrating 20 years of induced pluripotent stem cell (iPSC) technology. The three-day meeting took place from 20 to 22 October. It was organized with the Center for iPS Cell Research and Application at Kyoto University and co-sponsored by the Japanese Society for Regenerative Medicine. Registration filled up twice, even after the organizers moved the meeting to a larger venue. This showed the strong worldwide interest in a field that now covers basic research into cell identity and human development, disease models, drug discovery, the development of medical treatments, and therapies made from stem cells.
Jun Takahashi of CiRA chaired the opening main session. The speakers were Shinya Yamanaka of CiRA, Kyoto University, and the Gladstone Institutes; Janet Rossant, senior scientist emeritus at the SickKids Research Institute and editor-in-chief of Stem Cell Reports; and George Daley of Harvard Medical School. Yamanaka explained how iPSC technology developed from its discovery to clinical trials using cells and tissues made from iPSCs. He also discussed recent regulatory milestones in Japan, where two regenerative medical products made from iPSCs have received conditional approval for a limited time. He described scientific and practical challenges that still need to be solved.
Rossant discussed how iPSCs have changed research on pluripotent stem cells and opened new ways to study early human development using stem cell-based embryo models. She also discussed the ethical questions raised by these models. Daley spoke about changing cells into other cell types, how cells keep their identities, how they develop into specialized cells, how scientists model diseases, and how cells can be used as medicines. He also discussed the continuing difficulty of making blood-forming stem cells from iPSCs. Several scientific talks focused on what pluripotent stem cells can develop into, whether their genetic material stays stable, and whether they are safe to use.
Yasuhiro Takashima of Kyoto University discussed the wider developmental abilities of naïve human iPSCs. These cells can be used in human embryo models to study early development, implantation, and pregnancy-related disorders. They may also be useful in future regenerative medicine. Ivana Barbaric of the University of Sheffield described research into how genetic changes arise in human pluripotent stem cells and how cells with certain genetic changes can gain an advantage and grow more successfully in laboratory cultures. Assa Sherman of Hebrew University of Jerusalem presented research using genome-wide screening to identify genetic processes that affect tumor formation in human pluripotent stem cells.
The talks identified genetic stability, reliability, and the risk of tumors as major concerns when using these cells in research and developing future cell-based treatments. Maike Sander of the Max Delbrück Center for Molecular Medicine presented progress in making specially engineered islet organoids from stem cells for diabetes research. These small, lab-grown structures contain insulin-producing beta cells. Her work adds blood vessels and supporting cells to improve beta-cell function and build more complex models for studying diabetes and testing possible treatments.
The meeting report described laboratory research, not proof that a treatment works in patients. Another presentation by an early-career researcher examined how the immune system responds to replacement cells. Carl Andersson of Uppsala University used insulin-producing islets made from a patient's own stem cells to study how that patient's T cells enter the islets and damage them in type 1 diabetes. The research was presented as a way to gather information that could help improve future cell-replacement treatments. However, the supplied report did not describe a tested treatment or any results in patients.
A rapid-fire session featured 10 early-career scientists studying cell reprogramming, development, infection, and organ models. Mert Akgunduz of Kyoto University's Institute for the Advanced Study of Human Biology developed a human embryo model made from stem cells. The model recreates important parts of gastrulation and organ formation, including how tissues are arranged and how early organs begin to form. Xueying Fan of Westlake University presented a computer-based method for mapping how flexible cells are during reprogramming. The method identified a self-renewing state in human hypoblast stem cells that carry the OCT4 marker.
Dimitrios Valakos of the Biomedical Research Foundation of the Academy of Athens studied changes in the organization of chromatin, the material made from DNA and proteins, that help specialized cells become pluripotent and maintain that state. Ramon Pfaendler of the Botnar Institute of Immune Engineering at ETH Zürich combined advanced imaging, deep learning, and molecular profiling to study how cell shape and position relate to early changes in the types of cells that develop from human cells. Other short presentations used iPSC-based laboratory systems to study more specialized areas of human biology.
Sarah Stucchi of Human Technopole used neural organoids and models of germline cells to study how environmental chemicals, hormones, and genetic susceptibility affect development. The work also examined whether there are stages of development when people may be especially vulnerable to chemicals that interfere with hormones. Zacharie Taoufiq of the Okinawa Institute of Science and Technology introduced a deep nuclear proteomics platform for cell programming. The platform was designed to speed up the process of turning human iPSCs into heart muscle cells and helping them mature. Min Jung Kim of Ajou University described a human alveolar organoid model for studying infections caused by Mycobacterium abscessus, the role of macrophages in those infections, and the inflammation that follows. The goal was to provide a platform for evaluating possible treatments.
These projects showed the range of laboratory systems scientists are developing, but the symposium report provided no evidence that these approaches work as treatments in patients. Other presentations focused on bone and brain models. Souta Motoike of CiRA created assembloids of human jawbone tissue from iPSCs. These structures included networks of blood vessels and osteoclasts, which are cells that break down bone. They provide laboratory systems for studying jawbone biology and disease.
Marion Guillon of CHU Sainte-Justine and the Université de Montréal used human brain organoids with edited genes to model problems in early brain development linked to genetic changes associated with epilepsy. The aim was to study how these genetic changes disrupt early brain development and to gather information that might support future personalized treatments. Like the other organoid and assembloid research presented at the meeting, this work used laboratory models. It does not show that a treatment has been developed or proven to work in people.
The meeting connected iPSC research with questions about early development and the biological conditions that allow human cell systems to form. Rossant's presentation linked pluripotent stem cells to embryo models. Other talks examined naïve iPSCs, germline models, and stem cell-based structures that help organize developing tissues. These studies focused on tissue organization, implantation, how cells become specialized, and how environmental or genetic exposures affect development.
Models of gastrulation, the hypoblast, germline development, neural organoids, and jawbone assembloids with blood vessels each provided a different way to study biology in the laboratory. The program showed that iPSC technology is not limited to one use. Instead, it provides a platform for building models to study development, disease processes, possible treatments, and other questions about human biology. The meeting also highlighted practical, regulatory, and manufacturing challenges involved in turning iPSC research into medical treatments.
The announcement described ongoing clinical trials involving cells and tissues made from iPSCs, conditional approval for a limited time for two iPSC-derived regenerative medical products in Japan, and continued research into disease models, drug discovery, and large-scale manufacturing. It did not name the two products or explain what conditions they are intended to treat. It also did not provide trial results or details about the reasons for the approvals or how long they last. These milestones therefore cannot be assessed further using the supplied information. Similarly, many presentations described research methods, laboratory models, or new platforms rather than a combined set of clinical results.
The clearest reported achievement of the symposium was bringing together an international community whose meeting reached full capacity. Participants reviewed 20 years of iPSC research and discussed a wide range of approaches that are still being improved, evaluated, and developed for medical use.
Subject of Research: An international symposium reviewing progress in iPSC research and regenerative medicine
Article Title: Global stem cell research community gathers in Kyoto, Japan to celebrate 20 years of iPSC discovery and innovation
Article References: Global stem cell research community gathers in Kyoto, Japan to celebrate 20 years of iPSC discovery and innovation. Original publication (Bibliographic details unavailable.)
Image Credits: AI Generated
DOI: Not provided
Keywords: induced pluripotent stem cells, cell reprogramming, regenerative medicine, stem cell organoids, human development models, genetic stability, disease modeling, clinical translation, stem cell safety, Kyoto symposium, Global, stem